Cytomorphological analysis of histologically confirmed cases of medullary thyroid carcinoma

1 Jankowski J, Franklin J. Faculty Opinions recommendation of Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature. 2020. doi:10.341 0/f.734004835.793572727 Search in Google Scholar

2 Wells SA, Asa SL, Dralle H, Elisei R, Evans DB, Gagel RF, et al. Revised American Thyroid Association Guidelines for the Management of Medullary Thyroid Carcinoma. Thyroid. 2015. pp. 567–610. doi:10.1089/thy.2014.0335 Search in Google Scholar

3 Papaparaskeva K, Nagel H, Droese M. Cytologic diagnosis of medullary carcinoma of the thyroid gland. Diagn Cytopathol. 2000;22: 351–358. Search in Google Scholar

4 Pacini F, Castagna MG, Cipri C, Schlumberger M. Medullary Thyroid Carcinoma. Clinical Oncology. 2010. pp. 475–485. doi:10.1016/j.clon.2010.05.002 Search in Google Scholar

5 Elisei R, Bottici V, Cappagli V, Ramone T, Tacito A, Ciampi R, et al. Clinical utility of genetic diagnosis for sporadic and hereditary medullary thyroid carcinoma. Annales d’Endocrinologie. 2019. pp. 187–190. doi:10.1016/j.ando.2019.04.014 Search in Google Scholar

6 Kebebew E, Ituarte PHG, Siperstein AE, Duh Q-Y, Clark OH. Medullary thyroid carcinoma. Cancer. 2000. pp. 1139–1148. doi:10.1002/(sici)1097-0142(20000301)88:5<1139::aid-cncr26>3.0.co;2-z Search in Google Scholar

7 Bugalho MJ, Domingues R, Santos JR, Catarino AL, Sobrinho L. Mutation analysis of the RET proto-oncogene and early thyroidectomy: results of a Portuguese cancer centre. Surgery. 2007;141: 90–95. Search in Google Scholar

8 Elisei R, Romei C, Cosci B, Agate L, Bottici V, Molinaro E, et al. RET genetic screening in patients with medullary thyroid cancer and their relatives: experience with 807 individuals at one center. J Clin Endocrinol Metab. 2007;92: 4725–4729. Search in Google Scholar

9 Das T, Cagan R. Drosophila as a novel therapeutic discovery tool for thyroid cancer. Thyroid. 2010;20: 689–695. Search in Google Scholar

10 Brandi ML, Gagel RF, Angeli A, Bilezikian JP, Beck-Peccoz P, Bordi C, et al. Guidelines for diagnosis and therapy of MEN type 1 and type 2. J Clin Endocrinol Metab. 2001;86: 5658–5671. Search in Google Scholar

11 Jindrichová S, Vcelák J, Vlcek P, Neradilová M, Nemec J, Bendlová B. Screening of six risk exons of the RET proto-oncogene in families with medullary thyroid carcinoma in the Czech Republic. J Endocrinol. 2004;183: 257–265. Search in Google Scholar

12 Hodak SP, Burman KD. The Calcitonin Conundrum—Is It Time for Routine Measurement of Serum Calcitonin in Patients with Thyroid Nodules? The Journal of Clinical Endocrinology & Metabolism. 2004. pp. 511–514. doi:10.1210/jc.2003-031983 Search in Google Scholar

13 Mazzaferri EL. Value of routine measurement of serum calcitonin concentrations in patients with nodular thyroid disease: A multicenter study. Yearbook of Endocrinology. 2007. pp. 238–243. doi:10.1016/s0084-3741(08)70120-3 Search in Google Scholar

14 Heshmati HM, Gharib H, van Heerden JA, Sizemore GW. Advances and controversies in the diagnosis and management of medullary thyroid carcinoma. Am J Med. 1997;103: 60–69. Search in Google Scholar

15 Mezei T, Kolcsár M, Pașcanu I, Vielh P. False positive cases in thyroid cytopathology – the experience of a single laboratory and a systematic review. Cytopathology. 2021. doi:10.1111/cyt.12984 Search in Google Scholar

16 Nikiforov YE, Seethala RR, Tallini G, Baloch ZW, Basolo F, Thompson LDR, et al. Nomenclature Revision for Encapsulated Follicular Variant of Papillary Thyroid Carcinoma: A Paradigm Shift to Reduce Overtreatment of Indolent Tumors. JAMA Oncol. 2016;2: 1023–1029. Search in Google Scholar

17 Zhao L, Ma B. Radiomics Features of Different Sizes of Medullary Thyroid Carcinoma (MTC) and Papillary Thyroid Carcinoma (PTC) Tumors: A Comparative Study. Clin Med Insights Oncol. 2022;16: 11795549221097675. Search in Google Scholar

18 Liu M-J, Liu Z-F, Hou Y-Y, Men Y-M, Zhang Y-X, Gao L-Y, et al. Ultrasonographic characteristics of medullary thyroid carcinoma: a comparison with papillary thyroid carcinoma. Oncotarget. 2017;8: 27520–27528. Search in Google Scholar

19 Lei R, Wang Z, Qian L. Ultrasonic Characteristics of Medullary Thyroid Carcinoma: Differential From Papillary Thyroid Carcinoma and Benign Thyroid Nodule. Ultrasound Q. 2021 [cited 2 Jun 2021]. doi:10.1097/RUQ.0000000000000508 Search in Google Scholar

20 Rossi ED, Adeniran AJ, Faquin WC. Pitfalls in Thyroid Cytopathology. Surg Pathol Clin. 2019;12: 865–881. Search in Google Scholar

21 Szántó Z, Kun IZ, Jung J. Pajzsmirigyrák társulása autoimmun thyreoiditiszekkel. Orvostudományi Értesítő (Buletin of Medical Sciences). 2008;81: 103–107. Search in Google Scholar

22 Trimboli P, Treglia G, Guidobaldi L, Romanelli F, Nigri G, Valabrega S, et al. Detection rate of FNA cytology in medullary thyroid carcinoma: a meta-analysis. Clin Endocrinol . 2015;82: 280–285. Search in Google Scholar

23 Malheiros DC, Canberk S, Poller DN, Schmitt F. Thyroid FNAC: Causes of false-positive results. Cytopathology. 2018;29: 407–417. Search in Google Scholar

24 Pusztaszeri MP, Bongiovanni M, Faquin WC. Update on the Cytologic and Molecular Features of Medullary Thyroid Carcinoma. Advances In Anatomic Pathology. 2014. pp. 31–40. doi:10.1097/pap.0000000000000004 Search in Google Scholar

25 Chand G, Lal H, Mayilvaganan S, Jaiswal S, Prasad R, Siddiqui F, et al. Cytomorphological features of medullary thyroid carcinoma: An analysis based on 41 ultrasoundguided fine-needle aspiration specimens. World j endocr surg. 2018;10: 108–118. Search in Google Scholar

26 Liu C-Y, Chen C-C, Bychkov A, Agarwal S, Zhu Y, Hang J-F, et al. Constitutive Cytomorphologic Features of Medullary Thyroid Carcinoma Using Different Staining Methods. Diagnostics (Basel). 2021;11. doi:10.3390/diagnostics11081396 Search in Google Scholar

27 Trimboli P, Giannelli J, Marques B, Piccardo A, Crescenzi A, Deandrea M. Head-to-head comparison of FNA cytology vs. calcitonin measurement in FNA washout fluids (FNA-CT) to diagnose medullary thyroid carcinoma. A systematic review and meta-analysis. Endocrine. 2021;75: 33–39. Search in Google Scholar

28 Costante G, Meringolo D. Calcitonin as a biomarker of C cell disease: recent achievements and current challenges. Endocrine. 2020. pp. 273–280. doi:10.1007/s12020-019-02183-6 Search in Google Scholar

29 Vierhapper H, Niederle B, Bieglmayer C, Kaserer K, Baumgartner-Parzer S. Early diagnosis and curative therapy of medullary thyroid carcinoma by routine measurement of serum calcitonin in patients with thyroid disorders. Thyroid. 2005;15: 1267–1272. Search in Google Scholar

30 Gambardella C, Offi C, Patrone R, Clarizia G, Mauriello C, Tartaglia E, et al. Calcitonin negative Medullary Thyroid Carcinoma: a challenging diagnosis or a medical dilemma? BMC Endocr Disord. 2019;19: 45. Search in Google Scholar

31 Samà MT, Rossetto Giaccherino R, Gallo M, Felicetti F, Maletta F, Bonelli N, et al. Clinical challenges with calcitonin-negative medullary thyroid carcinoma. J Cancer Res Clin Oncol. 2016;142: 2023–2029. Search in Google Scholar

32 Kim SJ, Yun HJ, Shin S-J, Lee YS, Chang H-S. Serum Calcitonin-Negative Medullary Thyroid Carcinoma: A Case Series of 19 Patients in a Single Center. Frontiers in Endocrinology. 2021. doi:10.3389/fendo.2021.747704 Search in Google Scholar

33 Machens A, Lorenz K, Dralle H. Prediction of biochemical cure in patients with medullary thyroid cancer. British Journal of Surgery. 2020. pp. 695–704. doi:10.1002/bjs.11444 Search in Google Scholar

34 Kovacs CS, Ralston SH. Presentation and management of osteoporosis presenting in association with pregnancy or lactation. Osteoporosis International. 2015. pp. 2223–2241. doi:10.1007/s00198-015-3149-3 Search in Google Scholar

35 Verbeek HH, de Groot JWB, Sluiter WJ, Muller Kobold AC, van den Heuvel ER, Plukker JT, et al. Calcitonin testing for detection of medullary thyroid cancer in people with thyroid nodules. Cochrane Database Syst Rev. 2020;3: CD010159. Search in Google Scholar

36 Niederle MB, Scheuba C, Riss P, Selberherr A, Koperek O, Niederle B. Early Diagnosis of Medullary Thyroid Cancer: Are Calcitonin Stimulation Tests Still Indicated in the Era of Highly Sensitive Calcitonin Immunoassays? Thyroid. 2020;30: 974–984. Search in Google Scholar

37 Daniels GH. Screening for medullary thyroid carcinoma with serum calcitonin measurements in patients with thyroid nodules in the United States and Canada. Thyroid. 2011;21: 1199–1207. Search in Google Scholar

38 Gharib H, McConahey WM, Tiegs RD, Bergstralh EJ, Goellner JR, Grant CS, et al. Medullary thyroid carcinoma: clinicopathologic features and long-term follow-up of 65 patients treated during 1946 through 1970. Mayo Clin Proc. 1992;67: 934–940. Search in Google Scholar

39 Dottorini ME, Assi A, Sironi M, Sangalli G, Spreafico G, Colombo L. Multivariate analysis of patients with medullary thyroid carcinoma. Prognostic significance and impact on treatment of clinical and pathologic variables. Cancer. 1996;77: 1556–1565. Search in Google Scholar

40 Modigliani E, Cohen R, Campos JM, Conte-Devolx B, Maes B, Boneu A, et al. Prognostic factors for survival and for biochemical cure in medullary thyroid carcinoma: results in 899 patients. The GETC Study Group. Groupe d’étude des tumeurs à calcitonine. Clin Endocrinol . 1998;48: 265–273. Search in Google Scholar

41 Eng C, Clayton D, Schuffenecker I, Lenoir G, Cote G, Gagel RF, et al. The relationship between specific RET proto-oncogene mutations and disease phenotype in multiple endocrine neoplasia type 2. International RET mutation consortium analysis. JAMA. 1996;276: 1575–1579. Search in Google Scholar

42 Ito Y, Onoda N, Okamoto T. The revised clinical practice guidelines on the management of thyroid tumors by the Japan Associations of Endocrine Surgeons: Core questions and recommendations for treatments of thyroid cancer. Endocr J. 2020 Jul 28;67(7):669-717. Search in Google Scholar